MaxCyte logo
MXCTMaxCyte
Trade MXCT now
MaxCyte primary media

About MaxCyte

MaxCyte (NASDAQ:MXCT) specializes in cell engineering, providing essential tools and technologies that support the development and commercialization of cellular therapies and biotherapeutics. The company's cutting-edge Flow Electroporation technology and instruments facilitate the discovery, development, and manufacture of new therapies, particularly in the field of immune-oncology, cell therapy, and gene editing. MaxCyte aims to accelerate the fight against a wide range of diseases, including cancer, inherited diseases, and infectious diseases, by empowering researchers and pharmaceutical companies to unlock the full potential of their cell-based research. Serving a global clientele, MaxCyte is committed to innovation and excellence in supporting the advancement of science and medicine.

What is MXCT known for?

Snapshot

Public US
Ownership
1998
Year founded
138
Employees
Gaithersburg, United States
Head office
1 of 3
US Rank
Unknown
Sector
N/A
Sector rank
Loading Map...

Operations

All Locations
Gaithersburg, US

Products and/or services of MaxCyte

  • Flow Electroporation Technology - A platform facilitating high-performance cell engineering for research, bioprocessing, and therapeutic applications.
  • ExPERT instrument family - Includes ATx, STx, and GTx models tailored for advanced gene editing, cell therapy development, and protein expression optimization.
  • CARMA Platform - Utilizing mRNA-based cell therapies for developing treatments against solid tumors and other diseases through a proprietary cell therapy platform.
  • Life Sciences Research Instruments - Offering high-quality instruments and tools for cellular engineering, including electroporation buffers and accessories.
  • Clinical and Commercial Licensing - Provides partners with access to its technology for development of cell-based therapies, including several partnerships with leading pharmaceutical companies.
  • Cell Engineering Services - Custom service offerings to support the development and optimization of cell-based therapies, including process development and training.

MaxCyte executive team

  • Mr. Maher MasoudPresident, CEO & Executive Director
  • Mr. Douglas J. Swirsky CFA, CPAChief Financial Officer
  • Mr. Jay GelfmanSenior Vice President of Operations
  • Mr. Jack HorganSenior Vice President of Corporate Development
  • Ms. Ana-Paula Martins FernandesSenior Vice President of Global Sales
  • Ms. Jill MayerSenior Vice President of Human Resources

Connect with us

Disclaimer

Grafa is not a financial advisor. You should seek independent, legal, financial, taxation or other advice that relate to your unique circumstances.

Grafa is not liable for any loss caused, whether due to negligence or otherwise arising from the use of or reliance on the information provided directly or indirectly, by use of this platform.